The latest results from the third International Stroke Trial (IST-3) suggest that the drug has the potential to cut costs by reducing the demand for long-term care. Treatment for acute ischemic stroke ...
The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical use when used within 3 hours of stroke onset, according to an observational study published in this ...
ABU DHABI, UAE — Thrombolytic treatment with recombinant human pro-urokinase was non-inferior to alteplase in achieving an excellent functional outcome in acute ischemic stroke but showed a ...
Recombinant tissue plasminogen activator (rtPA; alteplase) is the only thrombolytic agent licensed for the treatment of patients with acute ischemic stroke. One of the conditions of licensing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback